Ophthalmic Powerhouse Emerges As Visiox And Ocuvex Merge

Visiox Pharmaceuticals Inc. has announced a definitive merger with Ocuvex Therapeutics Inc., a private company specializing in ophthalmic treatments with a promising pipeline of upcoming medicines. This merger is set to elevate the newly formed company as a major player in the eye care industry, backed by a comprehensive range of ophthalmic products.

With Visiox’s offerings, such as OMLONTI (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%, Ocuvex will significantly enhance its market reach and expedite the launch of these innovative therapies. Moving forward, the combined entity will operate under the Ocuvex brand, continuing Visiox’s mission to revolutionize the ophthalmic sector through strategic partnerships with eye care professionals.

Ryan S. Bleeks, CEO of Visiox mentioned, “The combination of Visiox and Ocuvex makes for a perfect match. We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”